Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hurlutin Lu-177 in Angiogenic Breast Cancer
NCT04469127Phase 2Not yet recruiting
- Sponsor
- Advanced Imaging Projects
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Advanced Imaging Projects. Primary endpoints: Safety and Adequacy of Dose (Specific Aim 1) at 6 months, Anti-tumor Activity and Efficacy (Specific Aim 2) at 6 months and 3 more. Planned start Sep 2024; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04469127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469127.